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Genome-wide Screen Identifies rs646776 near Sortilin
as a Regulator of Progranulin Levels in Human Plasma
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Recent studies suggest progranulin (GRN) is a neurotrophic factor. Loss-of-functionmutations in the progranulin gene (GRN) cause fron-
totemporal lobar degeneration (FTLD), a progressive neurodegenerative disease affecting ~10% of early-onset dementia patients. Using
an enzyme-linked immunosorbent assay, we previously showed that GRN is detectable in human plasma and can be used to predictGRN
mutation status. This study also showed a wide range in plasma GRN levels in non-GRNmutation carriers, including controls. We have
now performed a genome-wide association study of 313,504 single-nucleotide polymorphisms (SNPs) in 533 control samples and iden-
tified on chromosome 1p13.3 two SNPs with genome-wide significant association with plasma GRN levels (top SNP rs646776;
p ¼ 1.7 3 1030). The association of rs646776 with plasma GRN levels was replicated in two independent series of 508 controls
(p ¼ 1.9 3 1019) and 197 FTLD patients (p ¼ 6.4 3 1012). Overall, each copy of the minor C allele decreased GRN levels by ~15%.
SNP rs646776 is located near sortilin (SORT1), and the minor C allele of rs646776 was previously associated with increased SORT1
mRNA levels. Supporting these findings, overexpression of SORT1 in cultured HeLa cells dramatically reduced GRN levels in the condi-
tioned media, whereas knockdown of SORT1 increased extracellular GRN levels. In summary, we identified significant association of
a locus on chromosome 1p13.3 with plasma GRN levels through an unbiased genome-wide screening approach and implicated
SORT1 as an important regulator of GRN levels. This finding opens avenues for future research into GRN biology and the pathophys-
iology of neurodegenerative diseases.Progranulin (GRN) is a secreted growth factor expressed in
a variety of tissues and has many important cellular func-
tions, including the regulation of early embryogenesis,
wound repair, inflammation, and tumor formation.1
Recently, a novel role for GRN was suggested in the field
of neurobiology when we identified loss-of-function muta-
tions in the progranulin gene (GRN [MIM 138945]) as
a major cause of frontotemporal lobar degeneration
(FTLD [MIM 607485]).2,3
The term FTLD encompasses several different neurode-
generative diseases characterized by atrophy of the frontal
and temporal lobes of the brain.4 The clinical symptoms
associated with FTLD are also diverse and include behavior
and personality changes, language disorders of expression
and comprehension, cognitive impairment, and some-
times an extrapyramidal movement disorder or motor-
neuron disease.5 To date, there is no approved disease-
modifying drug or cure for FTLD, and pharmacological
treatment is predominantly aimed at the management of
symptoms such as difficult behaviors and cognitive impair-
ment.6
Since the identification of mutations in GRN in 2006,
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considerable progress has been made toward the study
GRN’s role in neurodegeneration. In vitro and in vivo func-
tional studies now suggest that GRN is a neurotrophic
factor involved in maintaining neuronal function during
aging.8–11 In this respect, it is interesting that a number
of potentially pathogenic GRN missense mutations have
also been identified in patients affected by neurodegenera-
tive diseases other than FTLD; such diseases includeAlz-
heimer disease (AD [MIM 104300]),12 amyotrophic lateral
sclerosis (ALS [MIM 105400]),13 and Parkinson disease
(MIM 168600).14 In addition, common genetic variants
in GRN have been associated with an increased risk for
disease in clinical AD series12,15 and a reduced survival in
patients with ALS.13 These findings suggest that a partial
loss of GRN function could also contribute to the neurode-
generative disease process in dementias other than FTLD.16
Using an enzyme-linked immunosorbent assay (ELISA),
we and others recently reported that GRN is detectable in
plasma,17,18 serum,19,20 and cerebrospinal fluid10,18 (CSF).
In plasma samples from a large cohort of Mayo Clinic Jack-
sonville FTLD patients and controls, we showed signifi-
cantly reduced levels of GRN in both symptomatic and
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Table 1. Cohort Description
Cohort N Agea (yr)
Females
(%) Sample Source (N Samples)
GWAS 533 73.1 5 4.3 61.2 Mayo Clinic Jacksonville (266)
Mayo Clinic Rochester (267)
Replication 508 77.8 5 7.5 57.9 Mayo Clinic Jacksonville (508)
FTLD 197 67.4 5 8.2 50.3 Mayo Clinic Jacksonville (197)
eQTL 359 51.2 5 26.1 34.0 University of Maryland
Brain Bank (228)
Johns Hopkins University
Brain Bank (36)
University of Miami
Brain Bank (17)
Sun Health Brain Bank (78)
One of the most common causes of death in the eQTL cohort was multiple
injuries, explaining the relatively young mean age at death in this cohort.
Subjects included in the GWAS, replication, and eQTL cohorts were healthy
non-Hispanic white individuals in whom a clinical history of neurological or
cerebrovascular disease was excluded, as was a diagnosis of cognitive impair-
ment. The ethnicity of the FTLD cohort was 98% non-Hispanic white individ-
uals, 1% Hispanic white individuals, and 1% Asian individuals. Subjects from
all cohorts agreed to be in the study and biological samples were obtained after
informed consent with ethical committee approval from the respective
institutions.
a Age is shown as the mean 5 standard deviation. Provided are the age at
blood draw of the subjects included in the GWAS, replication, and FTLD
cohorts and the age at death of subjects included in the eQTL cohort.patients without GRN mutations and controls.17 These
results indicated that plasma GRN levels are a reliable
biomarker for the detection of GRN mutations. Our anal-
ysis also indicated a wide range in plasma GRN levels,
even in healthy controls, suggesting that other genetic
and environmental factors play a role in regulating plasma
GRN levels. However, with the exception of genetic vari-
ants in GRN, no other genetic loci affecting GRN levels
are currently known.
To identify genetic loci that influence plasma GRN levels
and to further aid in our general understanding of GRN
biology, we undertook a genome-wide association study
(GWAS) of plasma GRN levels in a large cohort of healthy
controls. The identification of factors that could increase
the amount of GRN available to cells is important and
could form the basis for future disease-modifying therapies
for FTLD and related neurodegenerative diseases.
Subjects included in the GWAS cohort consisted of 533
healthy non-Hispanic white controls (Table 1), who had
been genotyped previously with Illumina HumanHap300
BeadChips as part of a GWAS that aimed to identify genes
for late-onset AD.21 All samples included in this study met
quality-control measures described in the AD GWAS publi-
cation.21 In addition, genotype clusters for the top 30
single-nucleotide polymorphisms (SNPs) with the most
significant p values in our GWAS were visually inspected,
and all SNPs were found to have satisfactory clusters. We
measured plasma GRN levels by using the Human Progra-
nulin Quantikine ELISA Kit (R&D Systems) and undiluted
plasma samples. To increase accuracy, we analyzed all
samples in duplicate. Readings from duplicate samples
with a coefficient of variation > 21.06% (n ¼ 15) were
excluded from further analysis. Known concentrations of
recombinant human GRN provided with the ELISA kit
were used as a standard. We used linear mixed-effects
models with natural logarithms of measured GRN levels,
including levels of six inter-plate control samples, to esti-
mate plate effects and to subtract these plate effects so as
to obtain GRN levels adjusted for plate-plate variation for
subsequent analysis. All analyses of GRN levels used loga-
rithms because of the skewed nature of the distributions,
and also because the log scale is more natural for esti-
mating the n-fold change.
We used linear-regression analyses in PLINK to test for
association between plasma GRN levels (by using the
natural log of the average, adjusted concentration) and
the 313,504 GWAS SNPs that met genotype quality
control. We used an additive model for each SNP (0, 1, or
2 minor alleles) and included age at blood draw, series
(Mayo Clinic Jacksonville and Mayo Clinic Rochester),
and sex as additional covariates. Two SNPs, rs646776 and
rs611917, located in the same chromosomal region at
1p13.3, showed genome-wide significant association
with plasma GRN levels (Table 2). The SNP with the most
significant p value, rs646776 (p ¼ 1.7 3 1030), is located
in a small linkage disequilibrium (LD) block containing
two genes: cadherin EGF LAG seven-pass G-type receptorThe American2 (CELSR2 [MIM 604265]) and proline/serine-rich coiled-
coil 1 (PSRC1 [MIM 613126]). This SNP was previously
shown to associate with mRNA expression levels of
CELSR2, PSRC1, and sortilin 1 (SORT1 [MIM 602458]),
which is located in an adjacent LD block at chromosome
1p13.3 (Figure 1).22,23 In the GWAS cohort, each copy of
the minor C allele of rs646776 decreased plasma GRN
levels by ~16% (Figure S1 available online).
To replicate these findings, we selected the two genome-
wide significant SNPs and the top 28 additional SNPs that
had nominal significant association with plasma GRN
levels at p < 1 3 104 for genotyping in our replication
cohort. This cohort consisted of 508 additional healthy
non-Hispanic white controls (Table 1), and we performed
genotyping with SEQUENOM’s MassArray iPLEX tech-
nology according to the manufacturer’s instructions.
PlasmaGRN levels were quantifiedwith theHuman Progra-
nulin Quantikine ELISA Kit (R&D Systems) as described for
theGWAScohort, andduplicate readingswere taken for495
samples passing quality control. We performed linear-
regression analyses in PLINK to test for association between
plasma GRN levels (by using the natural log of the average,
adjusted concentration) and the 30 SNPs by using an addi-
tivemodelwith age at blooddrawand sex as covariates.24 In
this cohort, rs646776 (p ¼ 1.9 3 1019) and rs611917
(p ¼ 2.3 3 108) were also significantly associated with
plasma GRN levels; there was a decrease of ~13% in plasma
GRN levels for each copy of the minor allele of rs646776
(Table 2, Figure S1). Among the other 28 SNPs included in
the replication analysis, one additional SNP, rs17586966,Journal of Human Genetics 87, 890–897, December 10, 2010 891
Table 2. SNPs Significantly Associated with Plasma GRN Levels
rs Number Position (NCBI Build 36) Minor Allele MAF
GWAS Cohort (N ¼ 518) Replication Cohort (N ¼ 495)
Beta SE p Value Beta SE p Value
rs646776 chr1:109,620,053 G 0.21 0.18 0.01 1.7 3 1030 0.14 0.02 1.0 3 1019
age 0.00 0.00 0.36 0.00 0.00 0.79
series 0.01 0.02 0.58
sex 0.07 0.02 8.9 3 105 0.09 0.02 1.7 3 106
rs611917 chr1:109,616,775 C 0.30 0.10 0.01 5.1 3 1013 0.08 0.01 2.3 3 1008
age 0.00 0.00 0.29 0.00 0.00 0.77
series 0.01 0.02 0.49
sex 0.07 0.02 2.3 3 104 0.09 0.02 2.1 3 106
rs17586966 chr1:109,757,092 C 0.06 0.10 0.02 7.7 3 1005 0.12 0.03 1.3 3 1004
age 0.00 0.00 0.31 0.00 0.00 0.69
series 0.00 0.02 0.83
sex 0.08 0.02 7.8 3 105 0.09 0.02 9.9 3 106
The estimated effect (beta) and its standard error (SE) as well as the unadjusted p values are shown for the two SNPs (rs646776 and rs611917) that achieved
genome wide-significance in the GWAS and for one additional SNP (rs17586966) that reached genome-wide significance when the GWAS and replication cohorts
were combined (p ¼ 3.2 3 108). The beta, SE, and p value are also shown for each of the covariates that were included in the linear-regression analyses: age at
blood draw, series (only in the GWAS), and sex. Whereas the GWAS cohort consisted of samples from the Mayo Clinic Jacksonville and the Mayo Clinic Rochester,
all the samples in the replication cohort came from the Mayo Clinic Jacksonville; therefore, series was not included as a covariate in the linear-regression analysis of
the replication cohort. With a global significance threshold of a ¼ 0.05, a Bonferroni correction for the 313,504 SNPs tested required a p value of 1.6 3 107 for
genome-wide significance. MAF ¼ minor allele frequency.also located at chromosome 1p13.3 and in moderate LD
with rs646776 (D0 ¼ 0.76; r2 ¼ 0.16), showed significant
association in the replication cohort (p ¼ 1.3 3 104),
further confirming the importance of this chromosomal
region in GRN regulation in plasma (Table 2, Table S2).
Finally, Taqman SNP genotyping of rs646776 in a third
cohort consisting of Mayo Clinic FTLD patients who did
not have GRNmutations and for whom plasma GRN levels
had previously been generated (Table 1)17 also showed
highly significant association (beta ¼ 0.18, SE ¼ 0.02,
p¼ 6.43 1012) according to linear-regression analysis cor-
rected for age and sex. Moreover, although plasma GRN
levels were reduced by at least 50% in all FTLD patients
with GRN mutations when these patients were compared
to non-GRNmutation carriers and controls,17 lower plasma
GRN levels were observed in GRN-mutation carriers who
had one copy as opposed to zero copies of the rs646776
C allele (CT: 11.4 5 3.7 ng/ml, n ¼ 4; TT: 18.0 5
6.3 ng/ml, n ¼ 12; R&D Systems ELISA).
Both the GWAS and the replication cohorts also showed
a significant association between plasma GRN levels and
sex, demonstrating consistently higher plasma GRN levels
in females than in males (GWAS cohort: beta ¼ 0.07,
SE ¼ 0.02, p ¼ 2 3 104. Replication cohort: beta ¼ 0.09,
SE¼0.02, p< 13104).No significant association between
plasma GRN levels and age was observed (GWAS cohort
p¼ 0.20, replication cohort p¼ 0.69).When the coefficient
of determination (r2) was used for estimating the propor-
tion of variance in log plasma GRN levels explained by
the rs646776 genotype in the additive regression model892 The American Journal of Human Genetics 87, 890–897, Decembthat includes age at draw, series, and sex as covariates,
only ~0.3% of the variance in plasma GRN levels was ex-
plained by age at draw, series heterogeneity, or sex; when
rs646776 was included, an additional ~21.4% was ex-
plained.
The minor C allele of rs646776, the most significantly
associated SNP identified in this study, was previously
shown to correlate with increased mRNA expression levels
of multiple genes in the chromosome 1p13.3 region. Two
independent groups reported significant associationof liver
transcript levels of CELSR2, PSRC1, and SORT1 with the
strongest regulatory effect observed for SORT1mRNA.22,23
SORT1 is known to be highly expressed in multiple cells,
including neurons within the brain, and has important
physiological roles, including acting as a receptor for neuro-
mediators and growth factors.25,26 These findings led us to
hypothesize that SORT1couldbe involved in the regulation
of GRN and prompted us to model the functional effects of
SORT1 overexpression and knockdown on GRN levels in
cell culture. First, we overexpressed full-length SORT1 in
HeLa cells, selected for their high levels of endogenous
GRN expression, and measured endogenous GRN levels in
the conditionedmedia and cell lysates by immunoblotting
5 days after transfection. SORT1-overexpressing cells
showed a dramatic reduction in GRN levels in the condi-
tioned media to 35% the levels of control transfected cells
(p < 0.001) (Figures 2A and 2C). No significant changes
were observed in the GRN levels in the cell lysates. We
further confirmed these studies by using two different
siRNAs targeting SORT1 to knockdown SORT1 prior toer 10, 2010
Figure 1. p Values for Association with Plasma GRN Levels in the Genome-wide Association Study with Genetic Architecture of the
Associated Region
(A) Association results by chromosome. The –log10 of the p value is shown for genotyped SNPs (squares). The red horizontal line indi-
cates the Bonferroni threshold of p ¼ 1.6 3 107, and the blue horizontal line indicates an arbitrarily chosen threshold for suggestive
association of p < 1.0 3 104.
(B) Schematic of chromosome 1 with genomic positions of genes within the associated region at chromosome 1p13.3. SARS¼ seryl-tRNA
synthetase, CELSR2 ¼ cadherin EGF LAG seven-pass G-type receptor 2, PSRC1 ¼ proline/serine-rich coiled-coil 1, MYBPHL ¼ myosin
binding protein H-like, SORT1 ¼ sortilin, PSMA5 ¼ proteasome subunit, alpha-type 5, SYPL2 ¼ synaptophysin-like 2, and ATXN7L2 ¼
ataxin 7-like 2.
(C) Linkage disequilibrium plot (Haploview 4.0, solid-spine haplotype block definition, r2 values with D0 color scheme) of the region en-
compassing the three SNPs (circled in red) that showed genome-wide significant association with plasma GRN levels in the combined
GWAS and replication cohort.immunoblotting. Knockdownof SORT1 resulted in a signif-
icant 70%–80% increase in GRN levels in the conditioned
media in comparison to cells transfected with a negative
control siRNA (p < 0.001 for both SORT1 siRNAs) (Figures
2B and 2D), whereas GRN levels in the cell lysates were
unchanged. Finally, we used a GRN ELISA to more accu-
rately quantify the significant changes in extracellular
levels ofGRN resulting from the overexpression and knock-
down of SORT1, which confirmed the immunoblot data
(Figure S2).
SORT1 is a member of the mammalian family of
neuronal receptors defined by the unique vps10-domain
that binds neurotrophic factors and neuropeptides.27,28 It
is an endocytic and intracellular sorting receptor contrib-
uting to the targeting of ligands to lysosomes and the sort-
ing between the golgi apparatus and the endosomes.
SORT1 also engages in signaling by triggering neuronal
apoptosis when forming a trimeric complex with the
pro-domain of pro-neurotrophins and the p75 neurotro-The Americanphic receptor.25,26,29 The mature SORT1 receptor binds
various ligands, including neurotensin,30 the proforms of
nerve growth factor-b,25 and brain-derived neurotrophic
factor.29 On the basis of these known properties of
SORT1, the significant effect of altered SORT1 levels on
extracellular free GRN observed in our cell-culture studies
would support either a direct or an indirect role for
SORT1 in the secretory trafficking of GRN or in GRN endo-
cytosis. In this regard, it is of interest that while our paper
was in preparation, SORT1 was identified in an unbiased
expression cloning screen as the principal neuronal
binding site for GRN.31 According to this study, GRN
binding to SORT1 on the cell surface is followed by rapid
endocytosis and delivery of GRN to lysosomes. This study
further showed that SORT1-mediated endocytosis of GRN
is a major determinant of GRN levels in both intracellular
and extracellular compartments, as demonstrated by
a significant elevation of GRN in both serum and brains
of mice lacking Sort1.31Journal of Human Genetics 87, 890–897, December 10, 2010 893
Figure 2. Changes in SORT1 Expression Alter the
Amount of GRN in the Media of Cultured HeLa Cells
(A) Lipofectamine 2000 (Invitrogen) was used for
transfection of HeLa cells at 60% confluency with
1 mg control vector (pCMV6-AC-mGFP; Origene) or
SORT1 (pCMV6-XL5-SORT1; Origene) pcDNA. The
media were replaced both 4 hr and 2 days after trans-
fection before cells were harvested at 5 days. Lysates
from these cells were prepared in radioactive immu-
noprecipitation assay (RIPA) buffer. Lysates and
media from their corresponding wells were diluted
with an equivalent volume of 23 Novex Tris-glycine
sodium-dodecyl sulfate (SDS) sample buffer (Invitro-
gen), and equal volumes were run on SDS-polyacryl-
amide gels (Invitrogen), transferred to Immobilon
membranes (Millipore), and immunoblotted. Anti-
bodies were used against GRN (1:1000; Invitrogen),
SORT1 (1:10,000; R&D Systems), or GFP (1:5000; In-
vitrogen). Using GAPDH (1:500,000; Meridian Life
Sciences) ensured equal protein loading.
(B) HeLa cells cultured as described above were trans-
fected with 5 nM negative-control siRNA (QIAGEN)
or SORT1-specific (SORT1_1 or SORT1_3; QIAGEN)
siRNAs via the HiPerFect transfection reagent
(QIAGEN). After 2 days, the cells were retransfected
with the same amount of siRNA and maintained
for an additional 3 days before harvesting and
immunoblotting took place as described above.
(C and D) Densitometric analysis of media and lysate
GRN levels in HeLa cells transfected as described in
(A) and (B), respectively, was done with an EPSON
Expression 1680 flatbed scanner and ImageJ software. Values in the graphs represent the mean5 SEM of six independent experiments.
Two-sample statistical analysis was performed with the two-sample Student’s t test (C). Additionally, siRNA experiment data were
analyzed with a one-way ANOVA followed by Tukey’s HSD post hoc test (D). *Differs from control vector (C) or negative control siRNA
(D); p < 0.001.The chromosomal region at 1p13.3, and rs646776 in
particular, received increased attention recently when
multiple studies identified strong association of this locus
with elevated low-density lipoprotein (LDL) cholesterol
levels in the blood and an increased risk for myocardial
infarction in humans.32–36 In fact, this locus shows the
strongest association with serum lipoproteins of any
genetic locus in the genome. The association with LDL
cholesterol levels in this region was recently explained by
the identification of rs12740374, a proxy of rs646776
(r2 ¼ 1.0), which alters the expression of SORT1 mRNA
specifically in the liver (by binding to a SORT1 liver-specific
transcription factor binding site) and thereby affects the
secretion of very low-density lipoproteins by liver cells.23
These recent findings suggest that although rs646776
shows an effect on GRN levels in the periphery because of
the regulation of SORT1 mRNA levels in the liver by its
proxy rs12740374, it is unlikely that rs646776 will show
association with brain expression levels of SORT1 mRNA.
To address this question and to determine whether other
SNPs at this locus are associated with SORT1 mRNA levels
in the brain, we next performed an expression quantitative
trait locus (eQTL) analysis by using cerebellum and frontal-
cortex brain samples from359non-Hispanicwhite controls
and 2,366 SNPs located in cis with SORT1, where cis is the
region 51 Mb from transcription start or end or within
the gene (Table 1, Figure 3). Processing and analysis of the894 The American Journal of Human Genetics 87, 890–897, Decembgenotype and mRNA expression data was performed in
a manner similar to methods previously described for
a study including 150 of these 359 subjects37 (GEO
accession number: GSE15745. dbGAP study accession
number: phs000249.v1.p1). Genotyping was performed
with DNA extracted from cerebellum tissue samples on
the Illumina HumanHap550 v3, Human610-Quad v1, and
Human660W-Quad v1 Infinium Beadchips. Subjects were
filtered with PLINK on the basis of genotype checks
including call rate, gender check, subject relatedness, and
population-outlier status.24 We then imputed genotypes
by using the CEU phased data from theMarch 2010 release
of the 1000 Genomes Project using Mach.38,39 Expression
profiling formRNA transcripts was assayed via the Illumina
HumanHT-12 v3 Expression Beadchip and normalized via
cubic spline. The SORT1 expression 50-mer probe was
checked for design issues with the ReMOAT tool.40 Subjects
were also filtered on the basis of their overall expression
profile; if an expression sample was found to be 53 stan-
dard deviations from the tissue groupmean in either detec-
tion rate or mean expression in either tissue, then the
subject was removed. After filtering based on genotype
and expression summary metrics, data for 322 subjects
passed our quality control andwere included in the analysis
(Figure 3). The expression data for SORT1 were then
adjusted for known covariates: age, sex, post-mortem
interval, originating tissuebank, preparation/hybridizationer 10, 2010
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Figure 3. Correlation of Brain SORT1 mRNA Transcripts with
Genotypes of SNPs Located within and Flanking SORT1
Manhattan plot for ~290 kb region around SORT1 on chromo-
some 1 in cerebellum (red) and frontal cortex (blue). Correlation
p values between SNPs and the SORT1 mRNA transcript are
shown. Conservative Bonferroni correction based on all 2,366
tests performed within a tissue revealed that none of the SNPs
reached the significance threshold of p¼ 2.13 105. We therefore
applied a second less conservative correction on the basis of a false
discovery rate (FDR)44 of 5% to test for suggestive association. This
threshold was p ¼ 4.4 3 104 and is indicated with a dashed line.
The x axis represents the physical position for the region on the
chromosome, and the y axis is the –log10 of the correlation p value.
The relative position of the SORT1 transcript is drawn as a black
arrow in the top portion of the plot. SNP rs646776, most signifi-
cantly associated with GRN levels in plasma, is indicated with
a black triangle in the bottom portion of the plot. The correspond-
ing p values for this SNP in cerebellum (p ¼ 0.56) and frontal
cortex (p ¼ 0.98) are indicated as black dots.batch, and principal components 1 and 2 as determined
from the identity-by-state pair-wise distances computed
with PLINK for our subjects.24 The SORT1 eQTL analysis
was then performed by linear regression of allele dosage
and SORT1 expression with mach2qtl.38,39
We did not detect a significant correlation between
rs646776 genotypes and SORT1 mRNA levels in brain
samples from either the cerebellum (p ¼ 0.56) or frontal
cortex (p ¼ 0.98) (Figure 3). Because rs646776 is therefore
unlikely to show an effect on levels of GRN in the brain,
it is not surprising that rs646776 was not associated with
an increased risk for FTLD-TDP in a recent GWAS study.
However, correlation of SORT1 mRNA levels with geno-
types for 2,366 SNPs located5 1 Mb from the mRNA tran-
script start or end site of SORT1 did show suggestive
association in cerebellum with 15 SNPs that were in strong
LD and were located in an approximately 15 kb region
about 50 kb upstream of SORT1 within intron 1 of CELSR2
(top SNP rs649281, p ¼ 1.4 3 104; Figure 3 and Table S2).
These genetic variants affecting SORT1 expression in theThe Americanbrain will be ideal candidates for future association studies
aimed at the identification of genetic risk factors or disease
modifiers in the development of FTLD and related disor-
ders.
In recent months, much interest has focused on plasma
GRN levels as both a surrogate marker for disease and as
a disease risk factor.41 The assumption has been that factors
associated with reduced levels of plasma GRN will increase
the risk of developing FTLD, and this was in part the ratio-
nale for the current study design. Using a genome-wide
association approach, we have now identified association
of rs646776 with levels of GRN in human plasma.
However, in contrast to the effect of GRN loss-of-function
mutations, which affect GRN levels in every tissue and
cell type, the effect of rs646776 on GRN presumably results
from a liver-specific regulation of SORT1,23 and therefore it
is unlikely that rs646776 will be associated with GRN levels
in the brain. This also explains the lack of genetic associa-
tion of rs646776 in the recent FTLD-TDP GWAS. Impor-
tantly, the finding that some factors might regulate GRN
in a tissue- or organ-specific manner suggests that plasma
GRN levels might not accurately reflect levels of GRN in
the brain of an individual subject. This discrepancy offers
a potential explanation for some of the previously pub-
lished unexpected results, including the lack of correlation
between plasma GRN levels and the onset age in families
harboring GRN mutations and the absence of reduced
plasma GRN levels in FTLD patient populations in
general.17,20 In the future, a careful examination of the
correlation between GRN levels in plasma and those in
brain tissue or CSF is clearly warranted so that the utility
of plasma GRN as a biomarker in FTLD can be determined.
With the exception of markers in the 1p13.3 chromo-
somal region near SORT1, our study did not identify other
SNPs with significant association with plasma GRN levels
in the GWAS and replication cohorts. The presence of addi-
tional, potentially rarer, functional variants not targeted by
the SNPs used in this study or variants with smaller effect
sizes for which our study might have been underpowered
cannot, however, be excluded. More importantly, the
current study does not exclude the possibility that in addi-
tion to SORT1, other transcripts coregulated by rs646776/
rs12740374 at the chromosome 1p13.3 locus might also
affect GRN regulation. Future in vitro functional analyses
systematically targeting each of the other candidate
proteins in this region will need to address this question.
It also remains possible that there are other GRN regulators
whose effects cannot be detected in human plasma. In fact,
the percentage of cis eQTLs that show tissue specificity has
now been suggested to be as high as 50%–90%.42,43 In this
regard it is important to note that, in the future, our
approach could be applied to other tissue types or bio-
fluids, including CSF, which could lead to the identifica-
tion of additional regulators of GRN and potential
therapeutic targets for FTLD.
In conclusion, we have used an unbiased genetic
approach to identify genes and proteins involved in theJournal of Human Genetics 87, 890–897, December 10, 2010 895
regulation of GRN and identified the multiligand receptor
SORT1 as a major regulator of extracellular GRN levels.
This finding opens avenues for future research into GRN
biology and the pathophysiology of neurodegenerative
diseases.Supplemental Data
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found with this article online at http://www.cell.com/AJHG/.Acknowledgments
The authors wish to acknowledge and thank the families who
contributed samples that were critically important to this study.
This work was supported by the National Institutes of Health
(grant numbers P50 AG16574 [Mayo Alzheimer’s Disease Research
Center, R.C.P. as PI; to R.R., N.R.G.-R., and S.G.Y.], U01 AG06576
[Mayo Alzheimer’s Disease Patient Registry: R.C.P. as PI], R01
NS065782 [to R.R.], and R01 AG18023 [to N.R.G.-R. and S.G.Y.]).-
This project was also generously supported by the Consortium for
Frontotemporal Dementia Research (to R.R.), the Robert and Clar-
ice Smith Postdoctoral Fellowship (to M.M.C.), the Robert and
Clarice Smith and Abigail Van Buren Alzheimer’s Disease Research
Program (to R.C.P., N.R.G.-R., and S.G.Y.), and the Palumbo Profes-
sorship in Alzheimer’s Disease Research (to S.G.Y.). I.R.M. was sup-
ported by the Canadian Institutes of Health Research Operating
(#74580) and the Pacific Alzheimer’s Disease Research Foundation.
This work was supported in part by the Intramural Research
Program of the National Institute on Aging, National Institutes
of Health, Department of Health and Human Services; project
number ZIA AG000932-03.
Received: October 7, 2010
Revised: November 4, 2010
Accepted: November 8, 2010
Published online: November 17, 2010Web Resources
The URLs for data presented herein are as follows:
1000 Genomes Project: http://1000genomes.org/
Alzheimer Disease & Frontotemporal Dementia Mutation Data-
base, http://www.molgen.ua.ac.be/FTDMutations/
Online Mendelian Inheritance in Man (OMIM), http://www.ncbi.
nlm.nih.gov/Omim/
PLINK, http://pngu.mgh.harvard.edu/purcell/plink/
UCSF Genome Browser, http://genome.ucsc.edu/
References
1. Bateman, A., and Bennett, H.P. (2009). The granulin gene
family: From cancer to dementia. Bioessays 31, 1245–1254.
2. Baker, M., Mackenzie, I.R., Pickering-Brown, S.M., Gass, J.,
Rademakers, R., Lindholm, C., Snowden, J., Adamson, J., Sado-
vnick, A.D., Rollinson, S., et al. (2006). Mutations in progranu-
lin cause tau-negative frontotemporal dementia linked to
chromosome 17. Nature 442, 916–919.
3. Cruts, M., Gijselinck, I., van der Zee, J., Engelborghs, S., Wils,
H., Pirici, D., Rademakers, R., Vandenberghe, R., Dermaut, B.,
Martin, J.J., et al. (2006). Null mutations in progranulin cause896 The American Journal of Human Genetics 87, 890–897, Decembubiquitin-positive frontotemporal dementia linked to chro-
mosome 17q21. Nature 442, 920–924.
4. Mackenzie, I.R., Neumann, M., Bigio, E.H., Cairns, N.J.,
Alafuzoff, I., Kril, J., Kovacs, G.G., Ghetti, B., Halliday, G.,
Holm, I.E., et al. (2010). Nomenclature and nosology for
neuropathologic subtypes of frontotemporal lobar degenera-
tion: an update. Acta Neuropathol. 119, 1–4.
5. Graff-Radford, N.R., and Woodruff, B.K. (2007). Frontotempo-
ral dementia. Semin. Neurol. 27, 48–57.
6. Mendez, M.F. (2009). Frontotemporal dementia: Therapeutic
interventions. Front Neurol. Neurosci. 24, 168–178.
7. Gijselinck, I., Van Broeckhoven, C., and Cruts, M. (2008).
Granulin mutations associated with frontotemporal lobar
degeneration and related disorders: An update. Hum. Mutat.
29, 1373–1386.
8. Ahmed, Z., Sheng, H., Xu, Y.F., Lin, W.L., Innes, A.E., Gass, J.,
Yu, X., Hou, H., Chiba, S., Yamanouchi, K., et al. (2010). Accel-
erated lipofuscinosis and ubiquitination in granulin knockout
mice suggest a role for progranulin in successful aging. Am. J.
Pathol. 177, 311–324.
9. Ryan, C.L., Baranowski, D.C., Chitramuthu, B.P., Malik, S., Li,
Z., Cao, M., Minotti, S., Durham, H.D., Kay, D.G., Shaw, C.A.,
et al. (2009). Progranulin is expressed within motor neurons
and promotes neuronal cell survival. BMC Neurosci. 10, 130.
10. Van Damme, P., Van Hoecke, A., Lambrechts, D., Vanacker, P.,
Bogaert, E., van Swieten, J., Carmeliet, P., Van Den Bosch, L.,
and Robberecht, W. (2008). Progranulin functions as a neuro-
trophic factor to regulate neurite outgrowth and enhance
neuronal survival. J. Cell Biol. 181, 37–41.
11. Yin, F., Banerjee, R., Thomas, B., Zhou, P., Qian, L., Jia, T.,
Ma, X., Ma, Y., Iadecola, C., Beal, M.F., et al. (2010). Exag-
gerated inflammation, impaired host defense, and neuropa-
thology in progranulin-deficient mice. J. Exp. Med. 207,
117–128.
12. Brouwers, N., Sleegers, K., Engelborghs, S., Maurer-Stroh, S.,
Gijselinck, I., van der Zee, J., Pickut, B.A., Van den Broeck,
M., Mattheijssens, M., Peeters, K., et al. (2008). Genetic vari-
ability in progranulin contributes to risk for clinically diag-
nosed Alzheimer disease. Neurology 71, 656–664.
13. Sleegers, K., Brouwers, N., Maurer-Stroh, S., van Es, M.A.,
Van Damme, P., van Vught, P.W., van der Zee, J., Serneels, S.,
De Pooter, T., Van den Broeck, M., et al. (2008). Progranulin
genetic variability contributes to amyotrophic lateral sclerosis.
Neurology 71, 253–259.
14. Nuytemans, K., Pals, P., Sleegers, K., Engelborghs, S., Corsmit, E.,
Peeters, K., Pickut, B., Mattheijssens, M., Cras, P., De Deyn, P.P.,
et al. (2008). Progranulin variability has nomajor role in Parkin-
son disease genetic etiology. Neurology 71, 1147–1151.
15. Viswanathan, J., Ma¨kinen, P., Helisalmi, S., Haapasalo, A.,
Soininen, H., and Hiltunen, M. (2009). An association study
between granulin gene polymorphisms and Alzheimer’s
disease in Finnish population. Am. J. Med. Genet. B. Neuro-
psychiatr. Genet. 150B, 747–750.
16. Rademakers, R., and Rovelet-Lecrux, A. (2009). Recent insights
into the molecular genetics of dementia. Trends Neurosci. 32,
451–461.
17. Finch, N., Baker, M., Crook, R., Swanson, K., Kuntz, K., Surt-
ees, R., Bisceglio, G., Rovelet-Lecrux, A., Boeve, B., Petersen,
R.C., et al. (2009). Plasma progranulin levels predict progranu-
lin mutation status in frontotemporal dementia patients and
asymptomatic family members. Brain 132, 583–591.er 10, 2010
18. Ghidoni, R., Benussi, L., Glionna, M., Franzoni, M., and
Binetti, G. (2008). Low plasma progranulin levels predict pro-
granulin mutations in frontotemporal lobar degeneration.
Neurology 71, 1235–1239.
19. Schofield, E.C., Halliday, G.M., Kwok, J., Loy, C., Double, K.L.,
and Hodges, J.R. (2010). Low serum progranulin predicts the
presence of mutations: A prospective study. J. Alzheimers Dis.
20. Sleegers, K., Brouwers, N., Van Damme, P., Engelborghs, S.,
Gijselinck, I., van der Zee, J., Peeters, K., Mattheijssens, M.,
Cruts, M., Vandenberghe, R., et al. (2009). Serum biomarker
for progranulin-associated frontotemporal lobar degenera-
tion. Ann. Neurol. 65, 603–609.
21. Carrasquillo, M.M., Zou, F., Pankratz, V.S., Wilcox, S.L., Ma, L.,
Walker, L.P., Younkin, S.G., Younkin, C.S., Younkin, L.H., Bis-
ceglio, G.D., et al. (2009). Genetic variation in PCDH11X is
associated with susceptibility to late-onset Alzheimer’s
disease. Nat. Genet. 41, 192–198.
22. Kathiresan, S., Melander, O., Guiducci, C., Surti, A., Burtt, N.P.,
Rieder, M.J., Cooper, G.M., Roos, C., Voight, B.F., Havulinna,
A.S., et al. (2008). Six new loci associated with blood low-
density lipoprotein cholesterol, high-density lipoprotein
cholesterol or triglycerides in humans. Nat. Genet. 40,
189–197.
23. Musunuru,K., Strong,A., Frank-Kamenetsky,M., Lee,N.E., Ah-
feldt, T., Sachs, K.V., Li, X., Li, H., Kuperwasser, N., Ruda, V.M.,
et al. (2010). Fromnoncoding variant to phenotype via SORT1
at the 1p13 cholesterol locus. Nature 466, 714–719.
24. Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira,
M.A., Bender, D., Maller, J., Sklar, P., de Bakker, P.I., Daly,
M.J., and Sham, P.C. (2007). PLINK: A tool set for whole-
genome association and population-based linkage analyses.
Am. J. Hum. Genet. 81, 559–575.
25. Nykjaer, A., Lee, R., Teng, K.K., Jansen, P., Madsen, P.,
Nielsen, M.S., Jacobsen, C., Kliemannel, M., Schwarz, E.,
Willnow, T.E., et al. (2004). Sortilin is essential for proNGF-
induced neuronal cell death. Nature 427, 843–848.
26. Jansen, P., Giehl, K., Nyengaard, J.R., Teng, K., Lioubinski, O.,
Sjoegaard, S.S., Breiderhoff, T., Gotthardt, M., Lin, F., Eilers, A.,
et al. (2007). Roles for the pro-neurotrophin receptor sortilin
in neuronal development, aging and brain injury. Nat. Neuro-
sci. 10, 1449–1457.
27. Hermey, G. (2009). The Vps10p-domain receptor family. Cell.
Mol. Life Sci. 66, 2677–2689.
28. Petersen, C.M., Nielsen, M.S., Nykjaer, A., Jacobsen, L., Tom-
merup, N., Rasmussen, H.H., Roigaard, H., Gliemann, J., Mad-
sen, P., and Moestrup, S.K. (1997). Molecular identification of
a novel candidate sorting receptor purified from human brain
by receptor-associated protein affinity chromatography.
J. Biol. Chem. 272, 3599–3605.
29. Teng, H.K., Teng, K.K., Lee, R., Wright, S., Tevar, S., Almeida,
R.D., Kermani, P., Torkin, R., Chen, Z.Y., Lee, F.S., et al.
(2005). ProBDNF induces neuronal apoptosis via activation
of a receptor complex of p75NTR and sortilin. J. Neurosci.
25, 5455–5463.
30. Mazella, J., Zsu¨rger, N., Navarro, V., Chabry, J., Kaghad,M., Ca-
put, D., Ferrara, P., Vita, N., Gully, D., Maffrand, J.P., and Vin-
cent, J.P. (1998). The 100-kDa neurotensin receptor is gp95/
sortilin, a non-G-protein-coupled receptor. J. Biol. Chem.
273, 26273–26276.
31. Hu, F., Padukkavidana, T., Vaegter, C.B., Brady, O.A., Zheng, Y.,
Mackenzie, I.R., Feldman, H.H., Nykjaer, A., and Strittmatter,The AmericanS.M. (2010). Sortilin-mediated endocytosis determines levels
of the frontotemporal dementia protein, progranulin. Neuron
68, 654–667.
32. Lu, Y., Feskens, E.J., Boer, J.M., Imholz, S., Verschuren, W.M.,
Wijmenga, C., Vaarhorst, A., Slagboom, E., Mu¨ller, M., and
Dolle´, M.E. (2010). Exploring genetic determinants of plasma
total cholesterol levels and their predictive value in a longitu-
dinal study. Atherosclerosis 213, 200–205.
33. Muendlein, A., Geller-Rhomberg, S., Saely, C.H., Winder, T.,
Sonderegger, G., Rein, P., Beer, S., Vonbank, A., and Drexel,
H. (2009). Significant impact of chromosomal locus 1p13.3
on serum LDL cholesterol and on angiographically character-
ized coronary atherosclerosis. Atherosclerosis 206, 494–499.
34. Ronald, J., Rajagopalan, R., Ranchalis, J.E., Marshall, J.K., Hat-
sukami, T.S., Heagerty, P.J., and Jarvik, G.P. (2009). Analysis of
recently identified dyslipidemia alleles reveals two loci that
contribute to risk for carotid artery disease. Lipids Health
Dis. 8, 52.
35. Sandhu, M.S., Waterworth, D.M., Debenham, S.L., Wheeler,
E., Papadakis, K., Zhao, J.H., Song, K., Yuan, X., Johnson, T.,
Ashford, S., et al; Wellcome Trust Case Control Consortium.
(2008). LDL-cholesterol concentrations: a genome-wide asso-
ciation study. Lancet 371, 483–491.
36. Kleber, M.E., Renner, W., Grammer, T.B., Linsel-Nitschke, P.,
Boehm, B.O., Winkelmann, B.R., Bugert, P., Hoffmann,
M.M., and Ma¨rz, W. (2010). Association of the single nucleo-
tide polymorphism rs599839 in the vicinity of the sortilin 1
gene with LDL and triglyceride metabolism, coronary heart
disease and myocardial infarction. The Ludwigshafen Risk
and Cardiovascular Health Study. Atherosclerosis 209,
492–497.
37. Gibbs, J.R., van der Brug, M.P., Hernandez, D.G., Traynor, B.J.,
Nalls, M.A., Lai, S.L., Arepalli, S., Dillman, A., Rafferty, I.P.,
Troncoso, J., et al. (2010). Abundant quantitative trait loci
exist for DNA methylation and gene expression in human
brain. PLoS Genet. 6, e1000952.
38. Li, Y., Willer, C., Sanna, S., and Abecasis, G. (2009). Genotype
imputation. Annu. Rev. Genomics Hum. Genet. 10, 387–406.
39. Li, Y., and Abecasis, G.R. (2006). Mach 1.0: Rapid haplotype
reconstruction and missing genotype inference. Am. J. Hum.
Genet. S79, 2290.
40. Barbosa-Morais, N.L., Dunning, M.J., Samarajiwa, S.A., Darot,
J.F., Ritchie, M.E., Lynch, A.G., and Tavare´, S. (2010). A re-
annotation pipeline for Illumina BeadArrays: Improving the
interpretation of gene expression data. Nucleic Acids Res.
38, e17.
41. Sleegers, K., Brouwers, N., and Van Broeckhoven, C. (2010).
Role of progranulin as a biomarker for Alzheimer’s disease.
Biomark Med 4, 37–50.
42. Dimas, A.S., Deutsch, S., Stranger, B.E., Montgomery, S.B.,
Borel, C., Attar-Cohen, H., Ingle, C., Beazley, C., Gutierrez Ar-
celus, M., Sekowska, M., et al. (2009). Common regulatory
variation impacts gene expression in a cell type-dependent
manner. Science 325, 1246–1250.
43. Emilsson, V., Thorleifsson, G., Zhang, B., Leonardson, A.S.,
Zink, F., Zhu, J., Carlson, S., Helgason, A., Walters, G.B., Gun-
narsdottir, S., et al. (2008). Genetics of gene expression and its
effect on disease. Nature 452, 423–428.
44. Benjamini, Y., and Hochberg, Y. (1995). Controlling the false
discovery rate: a practical and powerful approach to multiple
testing. J. R. Statist. Soc. B 57, 289–300.Journal of Human Genetics 87, 890–897, December 10, 2010 897
